Antibodies to alpha-synuclein and uses thereof

Abstract

The invention provides antibodies that specifically bind human α-synuclein with a high affinity and reduces α-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating α-synuclein antibodies, and methods of using α-synuclein antibodies for the treatment of diseases of the central nervous system, in particular alpha-synucleinopathies.

1 - 54 . (canceled) 
     
     
         55 . An antibody that binds to human α-synuclein, wherein the antibody comprises a L234F/L235E/P331S triple mutation in the Fc region. 
     
     
         56 . The antibody according to  claim 55 , wherein the antibody specifically binds the region between amino acid 102 and amino acid 130 within the C-terminal region of human α-synuclein. 
     
     
         57 . The antibody according to  claim 55 , wherein the antibody:
 a. binds monomeric and aggregated forms of α-synuclein;   b. binds monomeric and aggregated forms of α-synuclein in vivo;   c. sequesters both monomeric and aggregated forms of α-synuclein; and/or   d. sequesters both monomeric and aggregated forms of α-synuclein in vivo.   
     
     
         58 . The antibody according to  claim 55 , wherein the antibody:
 a. binds to α-synuclein with a K D  of less than 500 μM;   b. binds to monomeric α-synuclein with a K D  of less than 500 μM;   c. binds to monomeric human α-synuclein with a K D  of less than 500 μM; and/or   d. binds to recombinant bacterially expressed monomeric human avi-tag α-synuclein-Flag-His with a K D  of less than 500 μM,   optionally wherein the K D  is measured using Octet analysis.   
     
     
         59 . The antibody according to  claim 55 , wherein the antibody:
 a. binds to α-synuclein with a K D  of less than 400 μM, preferably less than 300 μM;   b. binds to monomeric α-synuclein with a K D  of less than 400 μM, preferably less than 300 μM;   c. binds to monomeric human α-synuclein with a K D  of less than 400 μM, preferably less than 300 μM; and/or   d. binds to recombinant bacterially expressed monomeric human biotinylated α-synuclein with a K D  of less than 400 μM, preferably less than 300 μM,   optionally wherein the K D  is measured using KinExA analysis.   
     
     
         60 . The antibody according to  claim 55 , wherein the antibody is a human antibody. 
     
     
         61 . The antibody according to  claim 55 , wherein the antibody:
 a. reduces α-synuclein spreading in vivo; and/or   b. binds to human, rat and cynomolgus α-synuclein.   
     
     
         62 . The antibody according to  claim 55 , wherein the antibody:
 a. competes with antibody aslo0452 ngl-3 for binding to human alpha-synuclein;   b. binds to the same epitope on human α-synuclein as antibody aslo0452 ngl-3;   c. binds to an epitope that is not required for aggregation; and/or   d. binds to an epitope that is not the same as the epitope bound by the 9E4 antibody.   
     
     
         63 . The antibody according to  claim 55 , wherein the antibody:
 a. binds to native endogenous human α-synuclein;   b. binds to native endogenous human α-synuclein in vivo;   c. binds disease relevant, pathological forms of α-synuclein;   d. binds disease relevant, pathological forms of α-synuclein in vivo;   e. reduces free unbound α-synuclein levels in the brain interstitial fluid; and/or   f. reduces free unbound α-synuclein levels in the brain interstitial fluid in vivo.   
     
     
         64 . The antibody according to  claim 55 , wherein the antibody comprises:
 a.
 i. three heavy chain CDRs having sequences:
 1. H-CDR1 of SEQ ID NO: 5 or a sequence differing from SEQ ID NO: 5 by 1, 2, 3, 4 or 5 single amino acid deletions, substitutions, or insertions; 
 2. H-CDR2 of SEQ ID NO: 15 or a sequence differing from SEQ ID NO: 15 by 1, 2, 3, 4 or 5 single amino acid deletions, substitutions, or insertions; and 
 3. H-CDR3 of SEQ ID NO: 16 or a sequence differing from SEQ ID NO: 16 by 1, 2, 3, 4 or 5 single amino acid deletions, substitutions, or insertions; and 
 
 ii. three light chain CDRs having sequences:
 1. L-CDR1 of SEQ ID NO: 20 or a sequence differing from SEQ ID NO: 20 by 1, 2, 3, 4 or 5 single amino acid deletions, substitutions, or insertions; 
 2. L-CDR2 of SEQ ID NO: 10 or a sequence differing from SEQ ID NO: 10 by 1, 2, 3, 4 or 5 single amino acid deletions, substitutions, or insertions; and 
 3. L-CDR3 of SEQ ID NO: 21 or a sequence differing from SEQ ID NO: 21 by 1, 2, 3, 4 or 5 single amino acid deletions, substitutions, or insertions; or 
 
   b.
 i. three heavy chain CDRs having sequences:
 1. H-CDR1 of SEQ ID NO: 5 or a sequence that maintains at least 80%, at least 85%, at least 90%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% and up to 99% sequence identity thereto; 
 2. H-CDR2 of SEQ ID NO: 15 or a sequence that maintains at least 80%, at least 85%, at least 90%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% and up to 99% sequence identity thereto; and 
 3. H-CDR3 of SEQ ID NO: 16 or a sequence that maintains at least 80%, at least 85%, at least 90%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% and up to 99% sequence identity thereto; and 
 
 ii. three light chain CDRs having sequences:
 1. L-CDR1 of SEQ ID NO: 20 or a sequence that maintains at least 80%, at least 85%, at least 90%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% and up to 99% sequence identity thereto; 
 2. L-CDR2 of SEQ ID NO: 10 or a sequence that maintains at least 80%, at least 85%, at least 90%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% and up to 99% sequence identity thereto; and 
 3. L-CDR3 of SEQ ID NO: 21 or a sequence that maintains at least 80%, at least 85%, at least 90%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% and up to 99% sequence identity thereto. 
 
   
     
     
         65 . A method of treating an α-synucleinopathy disease in a patient, the method comprising administering to the patient an antibody according to  claim 55 . 
     
     
         66 . The method according to  claim 65 , wherein the α-synucleinopathy is selected from Parkinson's Disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). 
     
     
         67 . The method according to  claim 65  wherein the disease is Parkinson's disease (PD). 
     
     
         68 . The method according to  claim 65 , wherein the disease is multiple system atrophy (MSA). 
     
     
         69 . A pharmaceutical composition comprising the antibody according to  claim 55  and a pharmaceutically acceptable excipient. 
     
     
         70 . An isolated nucleic acid molecule encoding the antibody according to  claim 55 . 
     
     
         71 . A host cell comprising a vector comprising the nucleic acid molecule of  claim 70 . 
     
     
         72 . A method of producing an antibody according to  claim 55 , the method comprising:
 (a) expressing the antibody from a nucleic acid that encodes said antibody; or   (b) culturing a host cell comprising a vector that encodes said antibody under appropriate conditions to produce the antibody;   optionally wherein the method further comprises isolating and/or purifying the antibody.